Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian court returns Teva's Copaxone process infringement suit

This article was originally published in Scrip

Executive Summary

An Indian court has returned Teva's suit against Natco Pharma in a case concerning the alleged infringement of a process patent (Indian patent No190759) for its multiple sclerosis drug, Copaxone (glatiramer acetate) over jurisdiction issues. Teva was seeking to block exports of Natco's generic glatiramer to the US and other countries claiming an infringement of its process patent.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC024620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel